Cadila Healthcare Limited And Its Subsidiary Zydus Pharmaceuticals (Usa) Inc. Announced That They Have Reached An Agreement With Celgene Corporation (Celgene), A Wholly Owned Subsidiary Of Bristol Myers Squibb Relating To Patents For Revlimid (Lenalidomide).As Part Of The Settlement, The Parties Will File Consent Judgments With The United States District Court For The District Of New Jersey That Enjoin Zydus Cadila From Marketing Generic Lenalidomide Before The Expiration Of The Patents-In-Suit, Except As Provided For In The Settlement.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!